Akari Therapeutics PLC (AKTX) Earning Somewhat Positive Media Coverage, Study Finds
Media headlines about Akari Therapeutics PLC (NASDAQ:AKTX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akari Therapeutics PLC earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 44.3198452040527 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of brokerages have issued reports on AKTX. Chardan Capital reiterated a “sell” rating and issued a $6.50 price target on shares of Akari Therapeutics PLC in a research note on Tuesday, April 25th. William Blair downgraded shares of Akari Therapeutics PLC from an “outperform” rating to a “market perform” rating in a report on Friday, May 12th. Zacks Investment Research downgraded shares of Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price target (down previously from $33.00) on shares of Akari Therapeutics PLC in a report on Monday, June 26th.
Shares of Akari Therapeutics PLC (NASDAQ:AKTX) traded up 2.38% during trading on Tuesday, reaching $3.87. 37,159 shares of the company traded hands. The firm’s 50 day moving average price is $4.66 and its 200-day moving average price is $7.85. Akari Therapeutics PLC has a 52 week low of $3.60 and a 52 week high of $22.20. The company’s market capitalization is $45.57 million.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.